- December 18, 2017
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Signs a Co-promotion Agreement with Janssen Pharmaceutical K.K. for Guselkumab, a Human Anti-interleukin (IL)-23 Monoclonal Antibody, in Japan
Taiho Pharmaceutical Co., Ltd. today announced that they signed on December 15, 2017 a co-promotion agreement with Janssen Pharmaceutical K.K (“Janssen”) for guselkumab in Japan. Guselkumab is a human anti-interleukin (IL)-23 monoclonal antibody for the treatment of psoriasis and palmoplantar pustulosis in Japan.
Under the terms of this agreement, Taiho Pharmaceutical obtains distribution rights for guselkumab in Japan. After Janssen obtains manufacturing and marketing approval, Taiho Pharmaceutical and Janssen will co-promote the product to medical professionals.
Guselkumab is a human monoclonal antibody with a novel mechanism of action that specifically targets (IL)-23. Janssen filed applications for manufacturing and marketing approval in Japan in April 2017 for indications of psoriasis vulgaris, arthropathic psoriasis, pustular psoriasis and erythrodermic psoriasis, which have not been effectively treated by existing treatments, followed by an application for the indication of palmoplantar pustulosis which have not been effectively treated by existing treatments, submitted in December 2017.
Taiho Pharmaceutical’s alliance with Janssen is expected to create new treatment options for patients with psoriasis and palmoplantar pustulosis. Taiho Pharmaceutical is committed to making greater contributions to patients and medical professionals in the field of dermatology.
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.